Single human B cell-derived monoclonal anti- Candida antibodies enhance phagocytosis and protect against disseminated candidiasis

Fiona Rudkin, Ingrida Raziunaite, Hillary Workman, Sosthene Essono, Rodrigo Belmonte, Donna M. MacCallum, Elizabeth M. Johnson, Lisete M. Silva, Angelina S. Palma, Ten Feizi, Allan Jensen, Lars P. Erwig, Neil A.R. Gow

Research output: Contribution to journalArticlepeer-review

Abstract

The high global burden of over one million annual lethal fungal infections reflects a lack of protective vaccines, late diagnosis and inadequate chemotherapy. Here, we have generated a unique set of fully human anti-Candida monoclonal antibodies (mAbs) with diagnostic and
therapeutic potential by expressing recombinant antibodies from genes cloned from the B cells of patients suffering from candidiasis. Single class switched memory B cells isolated from donors serum-positive for anti-Candida IgG were differentiated in vitro and screened against recombinant Candida albicans Hyr1 cell wall protein and whole fungal cell wall preparations.
Antibody genes from Candida-reactive B cell cultures were cloned and expressed in Expi293F human embryonic kidney cells to generate a panel of human recombinant anti- Candida mAbs that demonstrate morphology-specific, high avidity binding to the cell wall.
The species-specific and pan-Candida mAbs generated through this technology display favourable properties for diagnostics, strong opsono-phagocytic activity of macrophages in vitro, and protection in a murine model of disseminated candidiasis.
Original languageEnglish
Article number5288 (2018)
Number of pages16
JournalNature Communications
Volume9
Issue number1
DOIs
Publication statusPublished - 11 Dec 2018

Fingerprint

Dive into the research topics of 'Single human B cell-derived monoclonal anti- Candida antibodies enhance phagocytosis and protect against disseminated candidiasis'. Together they form a unique fingerprint.

Cite this